Skip to content

Study · Randomized controlled trial · n = 93 · 2008

9 results

Comparison of GnRH agonists and antagonists in normoresponder IVF/ICSI in Turkish female patients.

Moraloglu O, Kilic S, Karayalçin R, Yuksel B, Tasdemir N, Işik A, Ugur M

Advances in therapy1 Mar 2008Cited by 20 (Europe PMC)

PMID18345521 (opens in a new tab)DOI10.1007/s12325-008-0028-8 (opens in a new tab)PepBankPUB-18345521
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In normoresponder IVF/ICSI patients, cetrorelix was associated with fewer antral follicles than leuprolide (P<0.001).

    In plain wordsIn normoresponder IVF/ICSI patients, cetrorelix was associated with fewer antral follicles than leuprolide.

    Peptide
    Cetrorelix
    Outcome
    DecreaseAntral follicles
    Study

    n = 93

    Comparator
    Leuprolide acetate long protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg daily when follicles reached at least 14 mmAs given in this study (human).

    Source sentences

    Summary
    In Group II (the GnRHa group) more antral follicles (P<0.001), a longer induction duration (P=0.017) and higher peak E2 levels (P<0.001) were observed.
    3 context sentences
    Summary · context
    We randomised 93 patients undergoing IVF/ICSI between May 2005 and August 2006.
    Summary · context
    In Group I (n=45) a daily dose of GnRHant cetrorelix acetate 0.25 mg was administered when follicles reached a diameter of > or =14 mm.
    Summary · context
    Group II (n=48) patients were desensitised with the GnRHa, leuprolide acetate, in a long protocol.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In normoresponder IVF/ICSI patients, induction was shorter with cetrorelix than leuprolide (P=0.017).

    In plain wordsIn normoresponder IVF/ICSI patients, induction was shorter with cetrorelix than leuprolide.

    Peptide
    Cetrorelix
    Outcome
    DecreaseInduction duration
    Study

    n = 93

    Comparator
    Leuprolide acetate long protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg daily when follicles reached at least 14 mmAs given in this study (human).

    Source sentences

    Summary
    In Group II (the GnRHa group) more antral follicles (P<0.001), a longer induction duration (P=0.017) and higher peak E2 levels (P<0.001) were observed.
    3 context sentences
    Summary · context
    We randomised 93 patients undergoing IVF/ICSI between May 2005 and August 2006.
    Summary · context
    In Group I (n=45) a daily dose of GnRHant cetrorelix acetate 0.25 mg was administered when follicles reached a diameter of > or =14 mm.
    Summary · context
    Group II (n=48) patients were desensitised with the GnRHa, leuprolide acetate, in a long protocol.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In normoresponder IVF/ICSI patients, peak estradiol was lower with cetrorelix than leuprolide (P<0.001).

    In plain wordsIn normoresponder IVF/ICSI patients, peak estradiol was lower with cetrorelix than leuprolide.

    Peptide
    Cetrorelix
    Outcome
    DecreasePeak estradiol
    Study

    n = 93

    Comparator
    Leuprolide acetate long protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg daily when follicles reached at least 14 mmAs given in this study (human).

    Source sentences

    Summary
    In Group II (the GnRHa group) more antral follicles (P<0.001), a longer induction duration (P=0.017) and higher peak E2 levels (P<0.001) were observed.
    3 context sentences
    Summary · context
    We randomised 93 patients undergoing IVF/ICSI between May 2005 and August 2006.
    Summary · context
    In Group I (n=45) a daily dose of GnRHant cetrorelix acetate 0.25 mg was administered when follicles reached a diameter of > or =14 mm.
    Summary · context
    Group II (n=48) patients were desensitised with the GnRHa, leuprolide acetate, in a long protocol.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In normoresponder IVF/ICSI patients, retrieved oocyte numbers did not differ between cetrorelix and leuprolide (P=0.749).

    In plain wordsIn normoresponder IVF/ICSI patients, retrieved egg numbers did not differ between cetrorelix and leuprolide.

    Peptide
    Cetrorelix
    Outcome
    No significant changeOocytes retrieved
    Study

    n = 93

    Comparator
    Leuprolide acetate long protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg daily when follicles reached at least 14 mmAs given in this study (human).

    Source sentences

    Summary
    No differences were observed in the number of oocytes retrieved (P=0.749), embryos achieved and transferred (P=0.677), or fertilisation rates (P=0.839) between the two groups.
    3 context sentences
    Summary · context
    We randomised 93 patients undergoing IVF/ICSI between May 2005 and August 2006.
    Summary · context
    In Group I (n=45) a daily dose of GnRHant cetrorelix acetate 0.25 mg was administered when follicles reached a diameter of > or =14 mm.
    Summary · context
    Group II (n=48) patients were desensitised with the GnRHa, leuprolide acetate, in a long protocol.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In normoresponder IVF/ICSI patients, the number of embryos achieved and transferred did not differ between cetrorelix and leuprolide (P=0.677).

    In plain wordsIn normoresponder IVF/ICSI patients, the number of embryos achieved and transferred did not differ between cetrorelix and leuprolide.

    Peptide
    Cetrorelix
    Outcome
    No significant changeEmbryos achieved and transferred
    Study

    n = 93

    Comparator
    Leuprolide acetate long protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg daily when follicles reached at least 14 mmAs given in this study (human).

    Source sentences

    Summary
    No differences were observed in the number of oocytes retrieved (P=0.749), embryos achieved and transferred (P=0.677), or fertilisation rates (P=0.839) between the two groups.
    3 context sentences
    Summary · context
    We randomised 93 patients undergoing IVF/ICSI between May 2005 and August 2006.
    Summary · context
    In Group I (n=45) a daily dose of GnRHant cetrorelix acetate 0.25 mg was administered when follicles reached a diameter of > or =14 mm.
    Summary · context
    Group II (n=48) patients were desensitised with the GnRHa, leuprolide acetate, in a long protocol.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In normoresponder IVF/ICSI patients, fertilisation rates did not differ between cetrorelix and leuprolide (P=0.839).

    In plain wordsIn normoresponder IVF/ICSI patients, fertilisation rates did not differ between cetrorelix and leuprolide.

    Peptide
    Cetrorelix
    Outcome
    No significant changeFertilisation rate
    Study

    n = 93

    Comparator
    Leuprolide acetate long protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg daily when follicles reached at least 14 mmAs given in this study (human).

    Source sentences

    Summary
    No differences were observed in the number of oocytes retrieved (P=0.749), embryos achieved and transferred (P=0.677), or fertilisation rates (P=0.839) between the two groups.
    3 context sentences
    Summary · context
    We randomised 93 patients undergoing IVF/ICSI between May 2005 and August 2006.
    Summary · context
    In Group I (n=45) a daily dose of GnRHant cetrorelix acetate 0.25 mg was administered when follicles reached a diameter of > or =14 mm.
    Summary · context
    Group II (n=48) patients were desensitised with the GnRHa, leuprolide acetate, in a long protocol.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In normoresponder IVF/ICSI patients, clinical pregnancy rates did not differ significantly between cetrorelix and leuprolide (P=0.437).

    In plain wordsIn normoresponder IVF/ICSI patients, clinical pregnancy rates did not differ significantly between cetrorelix and leuprolide.

    Peptide
    Cetrorelix
    Outcome
    No significant changeClinical pregnancy rate
    Study

    n = 93

    Comparator
    Leuprolide acetate long protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg daily when follicles reached at least 14 mmAs given in this study (human).

    Source sentences

    Summary
    There was no statistically significant difference between groups in clinical pregnancy rates, cycle cancellation and ovarian hyperstimulation (P=0.437, P=0.109 and P=0.415, respectively).
    3 context sentences
    Summary · context
    We randomised 93 patients undergoing IVF/ICSI between May 2005 and August 2006.
    Summary · context
    In Group I (n=45) a daily dose of GnRHant cetrorelix acetate 0.25 mg was administered when follicles reached a diameter of > or =14 mm.
    Summary · context
    Group II (n=48) patients were desensitised with the GnRHa, leuprolide acetate, in a long protocol.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In normoresponder IVF/ICSI patients, cycle cancellation did not differ significantly between cetrorelix and leuprolide (P=0.109).

    In plain wordsIn normoresponder IVF/ICSI patients, cycle cancellation did not differ significantly between cetrorelix and leuprolide.

    Peptide
    Cetrorelix
    Outcome
    No significant changeCycle cancellation
    Study

    n = 93

    Comparator
    Leuprolide acetate long protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg daily when follicles reached at least 14 mmAs given in this study (human).

    Source sentences

    Summary
    There was no statistically significant difference between groups in clinical pregnancy rates, cycle cancellation and ovarian hyperstimulation (P=0.437, P=0.109 and P=0.415, respectively).
    3 context sentences
    Summary · context
    We randomised 93 patients undergoing IVF/ICSI between May 2005 and August 2006.
    Summary · context
    In Group I (n=45) a daily dose of GnRHant cetrorelix acetate 0.25 mg was administered when follicles reached a diameter of > or =14 mm.
    Summary · context
    Group II (n=48) patients were desensitised with the GnRHa, leuprolide acetate, in a long protocol.
  9. 09HumanRandomized controlled trialSafety outcome

    In normoresponder IVF/ICSI patients, ovarian hyperstimulation did not differ significantly between cetrorelix and leuprolide (P=0.415).

    In plain wordsIn normoresponder IVF/ICSI patients, ovarian hyperstimulation did not differ significantly between cetrorelix and leuprolide.

    Peptide
    Cetrorelix
    Outcome
    No significant changeOvarian hyperstimulation
    Study

    n = 93

    Comparator
    Leuprolide acetate long protocol
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.25 mg daily when follicles reached at least 14 mmAs given in this study (human).

    Source sentences

    Summary
    There was no statistically significant difference between groups in clinical pregnancy rates, cycle cancellation and ovarian hyperstimulation (P=0.437, P=0.109 and P=0.415, respectively).
    3 context sentences
    Summary · context
    We randomised 93 patients undergoing IVF/ICSI between May 2005 and August 2006.
    Summary · context
    In Group I (n=45) a daily dose of GnRHant cetrorelix acetate 0.25 mg was administered when follicles reached a diameter of > or =14 mm.
    Summary · context
    Group II (n=48) patients were desensitised with the GnRHa, leuprolide acetate, in a long protocol.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.